Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Targeted therapies offer high response rates but face acquired resistance.
• Immunotherapy provides durable responses in a subset of patients.
• Acquired resistance limits long-term efficacy of targeted cancer treatments.

Purpose of the Study:

• To review evidence on combining targeted therapy and immunotherapy for cancer.
• To explore the rationale behind combining these treatment modalities.
• To summarize current research on combination cancer therapies.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of evidence for immune effects of targeted therapies.
• Examination of clinical trial designs for combination therapies.

Main Results:

• Targeted therapies can modulate anti-tumor immunity.
• Combinations include immune checkpoint blockade and adoptive cell transfer with various targeted agents.
• Early evidence suggests potential for combined immunotherapy and targeted therapy.

Conclusions:

• Combined targeted therapy and immunotherapy is a promising cancer treatment strategy.
• Further optimization is required to enhance efficacy and manage toxicity.
• This approach warrants continued investigation across diverse cancer types.